| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Samalin, M Honciuc, P-M Llorc. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 41. issue 6. 2016-09-13. PMID:26603973. |
lurasidone is a new second-generation antipsychotic approved in march 2014 by the european medicines agency for the treatment of schizophrenia. |
2016-09-13 |
2023-08-13 |
Not clear |
| L Samalin, M Honciuc, P-M Llorc. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 41. issue 6. 2016-09-13. PMID:26603973. |
in open-label studies, lurasidone was associated with sustained improvement in efficacy measures observed and well-tolerated inpatients with schizophrenia who had switched to lurasidone from another antipsychotic. |
2016-09-13 |
2023-08-13 |
Not clear |
| L Samalin, M Honciuc, P-M Llorc. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 41. issue 6. 2016-09-13. PMID:26603973. |
although lurasidone long-acting formulation is lacking, the long-term profile of lurasidone appears compatible with a good acceptability and consequently a good compliance to treatment of patients with schizophrenia. |
2016-09-13 |
2023-08-13 |
Not clear |
| Leslie Citrom. Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient preference and adherence. vol 10. 2016-08-26. PMID:27563237. |
schizophrenia relapse, patient considerations, and potential role of lurasidone. |
2016-08-26 |
2023-08-13 |
Not clear |
| Leslie Citrom. Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient preference and adherence. vol 10. 2016-08-26. PMID:27563237. |
lurasidone is a second-generation (atypical) antipsychotic agent that is approved for the treatment of schizophrenia and bipolar depression. |
2016-08-26 |
2023-08-13 |
Not clear |
| Leslie Citrome, Peter J Weiden, Joseph P McEvoy, Christoph U Correll, Josephine Cucchiaro, Jay Hsu, Antony Loebe. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS spectrums. vol 19. issue 4. 2016-08-08. PMID:24330868. |
effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. |
2016-08-08 |
2023-08-12 |
Not clear |
| Leslie Citrome, Peter J Weiden, Joseph P McEvoy, Christoph U Correll, Josephine Cucchiaro, Jay Hsu, Antony Loebe. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS spectrums. vol 19. issue 4. 2016-08-08. PMID:24330868. |
to evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder patients switched to lurasidone. |
2016-08-08 |
2023-08-12 |
Not clear |
| Jennifer E Thomas, Joshua Caballero, Catherine A Harringto. The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. Current neuropharmacology. vol 13. issue 5. 2016-07-15. PMID:26467415. |
the incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. |
2016-07-15 |
2023-08-13 |
Not clear |
| Jonathan M Meyer, Yongcai Mao, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. International clinical psychopharmacology. vol 30. issue 6. 2016-07-06. PMID:26196189. |
weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. |
2016-07-06 |
2023-08-13 |
Not clear |
| Jonathan M Meyer, Yongcai Mao, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. International clinical psychopharmacology. vol 30. issue 6. 2016-07-06. PMID:26196189. |
the objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. |
2016-07-06 |
2023-08-13 |
Not clear |
| Jonathan M Meyer, Yongcai Mao, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. International clinical psychopharmacology. vol 30. issue 6. 2016-07-06. PMID:26196189. |
in summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months. |
2016-07-06 |
2023-08-13 |
Not clear |
| Andrew C McCreary, Adrian Newman-Tancred. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. Current pharmaceutical design. vol 21. issue 26. 2016-06-03. PMID:26044980. |
notably, interest has grown concerning 5-ht1a receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-ht1a receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-ht1a agonists on neurogenesis. |
2016-06-03 |
2023-08-13 |
Not clear |
| Yawen Jiang, Weiyi N. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. Journal of managed care & specialty pharmacy. vol 21. issue 9. 2016-06-01. PMID:26308225. |
health care utilization and treatment persistence associated with oral paliperidone and lurasidone in schizophrenia treatment. |
2016-06-01 |
2023-08-13 |
Not clear |
| Antony Loebel, Jane Xu, Jay Hsu, Josephine Cucchiaro, Andrei Pikalo. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences. vol 1358. 2016-05-23. PMID:26771990. |
lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia. |
2016-05-23 |
2023-08-13 |
Not clear |
| Antony Loebel, Leslie Citrome, Christoph U Correll, Jane Xu, Josephine Cucchiaro, John M Kan. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC psychiatry. vol 15. 2016-05-09. PMID:26521019. |
this design was embedded in a study intended to assess the efficacy of low dose lurasidone in patients with schizophrenia. |
2016-05-09 |
2023-08-13 |
Not clear |
| Philip D Harvey, Cynthia O Siu, Masaaki Ogasa, Antony Loebe. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophrenia research. vol 166. issue 1-3. 2016-05-02. PMID:26117157. |
effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. |
2016-05-02 |
2023-08-13 |
human |
| Philip D Harvey, Cynthia O Siu, Masaaki Ogasa, Antony Loebe. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophrenia research. vol 166. issue 1-3. 2016-05-02. PMID:26117157. |
we previously reported that treatment with 160mg/d of lurasidone improved cognitive performance in a manner superior to placebo, quetiapine xr 600mg/d, and lurasidone 80mg/d, based on a 6-week randomized trial of patients with an acute exacerbation of schizophrenia. |
2016-05-02 |
2023-08-13 |
human |
| Matthew Macaluso, Hala Kazanchi, Sheldon H Preskor. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia. Expert opinion on drug metabolism & toxicology. vol 11. issue 8. 2016-03-29. PMID:26173973. |
how the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia. |
2016-03-29 |
2023-08-13 |
Not clear |
| A Loebel, J Cucchiaro, R Silva, Y Mao, J Xu, A Pikalov, S R Marde. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. European psychiatry : the journal of the Association of European Psychiatrists. vol 30. issue 1. 2016-02-29. PMID:25280429. |
efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. |
2016-02-29 |
2023-08-13 |
Not clear |
| A Loebel, J Cucchiaro, R Silva, Y Mao, J Xu, A Pikalov, S R Marde. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. European psychiatry : the journal of the Association of European Psychiatrists. vol 30. issue 1. 2016-02-29. PMID:25280429. |
to evaluate the efficacy of lurasidone for schizophrenia using an established five-factor model of the positive and negative syndrome scale (panss). |
2016-02-29 |
2023-08-13 |
Not clear |